Biopharmaceutical Development: Digitization and Cell Therapies
BioPharm International® spoke with Jon Ellis, CEO, Trenchant BioSystems, about the commercial landscape for cell therapies and how digitization is impacting the industry.
There are a variety of new modalities in biopharmaceutical development that are influencing the overall industry. There are also new technologies, such as artificial intelligence (AI), machine learning, and digitization, that are pushing the industry into the future.
But how are these new technologies impacting the development and manufacturing of cell therapies? BioPharm International® spoke with Jon Ellis, CEO, Trenchant BioSystems, about where the cell therapy industry currently is and where it’s going in the future with the assistance of technology.
Ellis sees digitization as important for managing the manufacturing of cell therapies. “Most existing products have used manual, paper-driven batch records, [with] hundreds of pages,” Ellis says. “They're a nightmare to review. They can delay product release. It costs a lot of man hours to review them, and humans are terrible at reading hundreds of pieces of paper, looking for the one not performing items. So, digitalization is one of the key ways we're going to get the delivery of therapeutics to the patient more quickly, cheaply, and safely. That is absolutely paramount. There are some new companies out there now with the technologies which can be linked into manufacturing processes and control supply chain.”
Click the video above to watch the full interview.
About the speaker
Jon Ellis is CEO of Trenchant BioSystems.
